EDAP TMS(EDAP)

69120 VAULX EN VELIN, FranceBiotechnology

Focus: EDAP TMS is a France-based medical device company specializing in therapeutic ultrasound technology, primarily focused on high-intensity focused ultrasound (HIFU) for oncology and women's health indications. Public company with $69M revenue (FY 2025) operating at modest scale in a niche therapeutic modality.

Oncology Women's Health

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About EDAP TMS

AI assessmentNot Hiring

No open roles listed right now. Follow EDAP TMS to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$69M

Key Products

Focal One

Prostate Cancer

Growth

Lead marketed HIFU device for focal prostate cancer treatment; appears in multiple pipeline entries suggesting commercial availability but revenue not disclosed.

Pipeline & Clinical Trials

Help build intelligence for EDAP TMS

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Proprietary therapeutic ultrasound platform with 12 active clinical programs across prostate cancer, benign prostatic hyperplasia, and endometriosis—offering deep technical specialization in an underexplored modality
Public company status provides equity upside potential and established infrastructure without startup-level risk, with $31M cash runway in FY 2025
International footprint (France headquarters) combined with clinical trial activity across oncology and women's health creates exposure to emerging market adoption of HIFU technology

Watch Out For

Zero open job requisitions at time of analysis signals potential hiring freeze or structural consolidation, limiting near-term career mobility
Company is unprofitable (−$20.6M net income FY 2025) with only 12% R&D intensity and modest $69M revenue base—indicates limited resources for career development, competitive compensation, or rapid advancement
Pipeline skews heavily toward Phase 2 work with only 1 Phase 3 program; no approved products in revenue; long time horizon to meaningful clinical validation or regulatory wins

Generated by Claude from EDAP TMS's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

HIFU treatment in rectal Endometriosis

Endometriosis

N/A

Clinical Trials (1)

NCT05755958Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.

N/A

HIFU treatment

Endometriosis, Rectum

N/A

Clinical Trials (1)

NCT04494568Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Rectal Endometriosis

N/A